MindWalk Holdings Corp. filings document a foreign private issuer that furnishes Form 6-K reports for U.S. market disclosure. The company’s regulatory record includes earnings releases, IFRS-tagged financial data, press releases on Bio-Native AI platform developments, and exhibits covering technologies such as LensAI, HYFT, and B Cell Llama.
The filings also disclose capital-structure and governance items, including issued capital, restricted share units, stock options, lease liabilities, product sales, internally generated development costs, and corporate segment data. Separate 6-K submissions provide SEDI insider activity reports, reflecting the company’s foreign private issuer treatment and exemption from Section 16 Form 4 reporting requirements.
MindWalk Holdings Corp. (HYFT) launched an at-the-market offering of up to U.S.$30,000,000 in common shares through JonesTrading as sales agent. Sales may be made on Nasdaq under Rule 415(a)(4). JonesTrading will earn a 3.0% commission, and there is no escrow. The shares will not be sold in Canada. HYFT last closed at U.S.$1.76 on November 4, 2025.
MindWalk expects to use any net proceeds for research and development, capital expenditures (including laboratory expansion), working capital and general corporate purposes, and it may allocate a portion to repurchase securities or pursue complementary investments or acquisitions. Common shares outstanding were 46,157,312 as of July 31, 2025.
MindWalk Holdings Corp. furnished a Form 6-K that includes Exhibit 99.1, a Revised Statement of Executive Compensation dated November 6, 2025.
The company states that Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3. The report was signed by Chief Executive Officer Jennifer Bath.
MindWalk Holdings Corp. filed a Form S-8 registering 5,620,254 common shares issuable under the ImmunoPrecise Antibodies Ltd. 2025 Stock Incentive Plan. The shares may be issued through equity awards, including options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents, or other stock-based awards.
The company is a non-accelerated filer and an emerging growth company. Standard indemnification provisions for directors and officers under the British Columbia Business Corporations Act and the company’s articles are described, along with related insurance coverage.